Avalo Therapeutics Inc Stock Price, News & Analysis

Avalo Therapeutics (NASDAQ: AVTX) completed enrollment in its Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa (~250 adults) and expects topline data in mid-2026. The company appointed Kevin Lind to the board and added senior leaders in business development and HR. As of September 30, 2025, cash, cash equivalents and short-term investments totaled approximately $111.6 million, which the company said is expected to fund operations into 2028. For Q3 2025, R&D was $13.6M, G&A was $5.6M, and net loss was $30.6M (basic loss per share $2.19).

Avalo Therapeutics (Nasdaq: AVTX) announced management will participate in four investor conferences in November–December 2025 with scheduled fireside chats:

• Guggenheim Healthcare Innovation Conference — Nov 10, 2025 at 4:00 pm ET
• Stifel 2025 Healthcare Conference — Nov 12, 2025 at 2:40 pm ET
• TD Cowen Immunology & Inflammation Summit — Nov 13, 2025 at 9:00 am ET
• Piper Sandler 37th Annual Healthcare Conference — Dec 2, 2025 at 10:30 am ET

Live webcasts and archived replays (available for at least 30 days when provided) will be posted under News / Events in the Investors section at https://ir.avalotx.com.

Avalo Therapeutics (Nasdaq: AVTX) announced completion of enrollment in its Phase 2 LOTUS trial of AVTX-009 for adults with hidradenitis suppurativa (HS).

The trial exceeded its target of 222 patients with approximately 250 patients enrolled. LOTUS is a randomized, double-blind, placebo-controlled Phase 2 study (1:1:1) testing two AVTX-009 dose regimens versus placebo during a 16-week treatment phase. The primary endpoint is the proportion achieving HiSCR75 at Week 16. Secondary measures include HiSCR50/90, IHS4, draining fistula count, AN count, and PGA Skin Pain reductions. Topline data are expected in mid-2026. Trial identifiers: NCT06603077 and www.lotustrial.com.

Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has announced two key leadership appointments. Taylor Boyd joins as Chief Business Officer, bringing 15 years of experience and a track record of executing over $40 billion in M&A and capital markets transactions. Ashley Ivanowicz joins as SVP of Human Resources with 20 years of biotech HR experience.

The appointments come as Avalo prepares for its LOTUS Phase 2 trial of AVTX-009 in hidradenitis suppurativa, with data expected mid-2026. As part of their inducement packages, Boyd and Ivanowicz received 275,000 and 100,000 stock options respectively, vesting over four years with a one-year cliff.

Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has appointed Kevin R. Lind to its Board of Directors. Lind brings over 20 years of leadership experience in capital markets and business development, most notably leading Longboard Pharmaceuticals to a $2.6 billion acquisition by H. Lundbeck A/S in 2024.

The appointment comes as Avalo advances AVTX-009 through Phase 2 LOTUS trial in hidradenitis suppurativa (HS), with topline data expected mid-2026. Throughout his career, Lind has raised over a billion dollars for biotech companies and held key positions at Arena Pharmaceuticals, TPG, and Lehman Brothers.

Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.

Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech company focused on IL-1β-based treatments, reported Q2 2025 financial results and business updates. The company's Phase 2 LOTUS trial for hidradenitis suppurativa (HS) has enrolled over 75% of planned patients, with topline data expected mid-2026.

Financial highlights include $113.3 million in cash and short-term investments as of June 30, 2025, providing runway into 2028. Q2 2025 showed a net loss of $20.8 million ($1.92 per share), compared to net income of $98.5 million in Q2 2024. R&D expenses increased by $9.5 million to $14.1 million, primarily due to LOTUS trial costs.

The company strengthened its leadership by appointing Rita Jain, M.D. to the Board of Directors, bringing valuable experience in clinical development and regulatory strategy.

Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences. Management will conduct a fireside chat at the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:00 am ET. Additionally, they will participate in 1x1 meetings at the BTIG Virtual Biotechnology Conference 2025, scheduled for July 29-30, 2025. Webcasts and replays will be available on the company's investor relations website for at least 30 days after the events.

Avalo Therapeutics (AVTX) has appointed Rita Jain, M.D. to its Board of Directors. Dr. Jain brings over 20 years of leadership experience in biopharmaceutical development, clinical strategy, and regulatory affairs. She most recently served as Executive VP and Chief Medical Officer at ChemoCentryx, where she advanced Tavneos for ANCA-associated vasculitis. Her appointment comes as Avalo advances AVTX-009, an anti-IL-1β monoclonal antibody, through Phase 2 trials for hidradenitis suppurativa (HS), with results expected mid-2026. Dr. Jain previously held leadership positions at Akebia Therapeutics, AbbVie, Pfizer, and Immunovant, and currently serves on the boards of Celldex Therapeutics and AnaptysBio. She received her M.D. from SUNY Stony Brook and completed specialized training in rheumatology.